
Corcept Therapeutics Incorporated CORT
$ 38.33
-5.29%
Annual report 2025
added 02-24-2026
Corcept Therapeutics Incorporated Operating Cash Flow 2011-2026 | CORT
Annual Operating Cash Flow Corcept Therapeutics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 M | 198 M | 127 M | 120 M | 168 M | 152 M | 136 M | 116 M | 60.9 M | 18.4 M | - | - | -37.1 M | -36 M | -27.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 198 M | -37.1 M | 87.5 M |
Quarterly Operating Cash Flow Corcept Therapeutics Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 5.13 M | - | - | 23.8 M | - | - | 26 M | - | 86.9 M | - | 35.2 M | - | 118 M | - | 25.4 M | - | 117 M | 86.5 M | 33.3 M | - | 87.7 M | 49.2 M | 23.7 M | - | 94.1 M | 49.6 M | 34.4 M | - | 36.1 M | 25.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.6 M | - | -27.3 M | -18 M | -10.2 M | - | -21.1 M | -14.5 M | -7.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 118 M | -27.3 M | 33.9 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M | ||
|
Amarin Corporation plc
AMRN
|
6.73 M | $ 14.6 | -0.54 % | $ 6.06 B | ||
|
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | ||
|
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | ||
|
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | ||
|
Cabaletta Bio
CABA
|
-131 M | $ 2.8 | 0.67 % | $ 281 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | ||
|
Editas Medicine
EDIT
|
-165 M | $ 2.32 | - | $ 206 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-13 M | $ 1.1 | -8.75 % | $ 22.6 M | ||
|
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | ||
|
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | ||
|
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | ||
|
Eton Pharmaceuticals
ETON
|
10.5 M | $ 23.69 | -0.63 % | $ 637 M | ||
|
Esperion Therapeutics
ESPR
|
-13.1 M | $ 2.86 | 3.62 % | $ 594 M | ||
|
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | ||
|
EyePoint Pharmaceuticals
EYPT
|
-240 M | $ 13.05 | - | $ 956 K | ||
|
Equillium
EQ
|
-22.7 M | $ 2.06 | - | $ 118 M | ||
|
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | ||
|
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.32 | -1.13 % | $ 337 M | ||
|
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | ||
|
Halozyme Therapeutics
HALO
|
652 M | $ 63.36 | 0.19 % | $ 7.59 B | ||
|
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B | ||
|
Savara
SVRA
|
-101 M | $ 5.26 | -0.47 % | $ 1.17 B | ||
|
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | ||
|
Harmony Biosciences Holdings
HRMY
|
348 M | $ 27.52 | -0.25 % | $ 1.58 B | ||
|
Heron Therapeutics
HRTX
|
-27.6 M | $ 0.82 | 3.09 % | $ 137 M | ||
|
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
-92.1 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-75.6 M | - | - | $ 3.74 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | ||
|
Avid Bioservices
CDMO
|
11 M | - | - | $ 789 M | ||
|
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | ||
|
Iterum Therapeutics
ITRM
|
-26.8 M | $ 0.18 | 2.15 % | $ 3.55 M | ||
|
Bellerophon Therapeutics
BLPH
|
-17.8 M | - | -74.18 % | $ 955 K | ||
|
Johnson & Johnson
JNJ
|
24.5 B | $ 240.05 | 0.03 % | $ 578 B | ||
|
Kala Pharmaceuticals
KALA
|
-29.4 M | $ 0.21 | -3.22 % | $ 797 K |